Understanding SGLT2 Inhibitors (Jardiance, Farxiga)

SGLT2 inhibitors, such as Jardiance and Farxiga, are a class of medications used to treat type 2 diabetes. They work by blocking the action of the sodium-glucose cotransporter 2 (SGLT2) in the kidneys, which helps to reduce glucose reabsorption and increase glucose excretion in the urine.

How SGLT2 Inhibitors Work

SGLT2 inhibitors work by blocking the SGLT2 protein in the kidneys, which is responsible for reabsorbing glucose back into the bloodstream. By blocking this protein, SGLT2 inhibitors reduce the amount of glucose that is reabsorbed and increase the amount of glucose that is excreted in the urine. This process helps to lower blood glucose levels and improve glycemic control.

Benefits of SGLT2 Inhibitors

SGLT2 inhibitors have several benefits, including: * Improved glycemic control: SGLT2 inhibitors can help to lower blood glucose levels and improve glycemic control. * Weight loss: SGLT2 inhibitors can help to promote weight loss by reducing glucose reabsorption and increasing glucose excretion. * Reduced cardiovascular risk: SGLT2 inhibitors have been shown to reduce the risk of cardiovascular events, such as heart attacks and strokes. * Potential kidney benefits: SGLT2 inhibitors may help to reduce the risk of kidney disease and slow the progression of kidney disease.

Common SGLT2 Inhibitors

Some common SGLT2 inhibitors include: * Jardiance (empagliflozin) * Farxiga (dapagliflozin) * Invokana (canagliflozin) * Steglatro (ertugliflozin) * Xigduo XR (dapagliflozin and metformin) Hyperglycemia Symptoms 10 Signs Your Blood Sugar Is Dangerously High

Side Effects of SGLT2 Inhibitors

SGLT2 inhibitors can cause several side effects, including: * Increased urination: SGLT2 inhibitors can cause an increase in urine production, which can lead to dehydration if not managed properly. * Increased risk of genital mycotic infections: SGLT2 inhibitors can increase the risk of genital mycotic infections, such as yeast infections. * Increased risk of diabetic ketoacidosis: SGLT2 inhibitors can increase the risk of diabetic ketoacidosis, particularly in patients who are also taking other diabetes medications. * Increased risk of kidney problems: SGLT2 inhibitors may increase the risk of kidney problems, particularly in patients with pre-existing kidney disease. Surprising Things That Can Spike Your Blood Sugar Levels

Contraindications of SGLT2 Inhibitors

SGLT2 inhibitors are contraindicated in several situations, including: * Severe kidney problems: SGLT2 inhibitors are contraindicated in patients with severe kidney problems, particularly those with end-stage renal disease. * Severe liver problems: SGLT2 inhibitors are contraindicated in patients with severe liver problems, particularly those with liver failure. * Diabetic ketoacidosis: SGLT2 inhibitors are contraindicated in patients with diabetic ketoacidosis, particularly those who are also taking other diabetes medications. Normal Blood Sugar For Adults Your Guide To Fasting And Post Meal Ranges

Dosing and Administration of SGLT2 Inhibitors

SGLT2 inhibitors are typically taken once daily, with or without food. The recommended dose of SGLT2 inhibitors varies depending on the specific medication and the patient's condition. Patients should follow the recommended dosing schedule and consult with their healthcare provider if they have any questions or concerns.

Conclusion

SGLT2 inhibitors, such as Jardiance and Farxiga, are a class of medications used to treat type 2 diabetes. They work by blocking the SGLT2 protein in the kidneys, which helps to reduce glucose reabsorption and increase glucose excretion in the urine. SGLT2 inhibitors have several benefits, including improved glycemic control, weight loss, and reduced cardiovascular risk. However, they can also cause several side effects, including increased urination, genital mycotic infections, and diabetic ketoacidosis. Patients should carefully follow the recommended dosing schedule and consult with their healthcare provider if they have any questions or concerns.